CatalystMarker
← board

MYGN

distress 3/10 · well-funded / low risk
$5.68+0%today-31% from 52w high
myriad.com2,700 employeesFounded 1991Salt Lake City, UTDiagnostics & Research
Revenue
$200M
Liquidity
$124M
Runway
Shares 1y
+2%

Price & events

-6.3% over 6M
$3.55$4.93$6.31Jan 26Apr 26Jul 2617.6Mdilution: EFFECT shelf_effective (2026-03-04)dilution: 424B3 offering (2026-03-04)dilution: S-3 shelf_registration (2026-02-24)rating: Wells Fargo: Equal-Weight (2026-05-06)rating: TD Cowen: Hold (2026-05-06)rating: UBS: Neutral (2026-02-24)rating: Wells Fargo: Equal-Weight (2026-02-24)
CatalystRating changeDilutionFinancingdashed = today
+0.4%
1D
-8.2%
1W
+22.7%
1M
+18.6%
3M
-3.2%
6M
+19.8%
1Y
-79.7%
2Y
-82.1%
5Y
-71.5%
All

Overview

Market Cap
$536.47M
Enterprise Value
$532.37M
Volume
99.25K
52 Week Range
$3.55 – $8.18
Total Shares
94.45M
Float Shares
85.99M
Short %
9.30%
% Held by Insiders
3.76%
% Held by Institutions
95.77%
RVOL
0.07x
Beta
1.64

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 3

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 94,448,210 · 1 offerings/1y · 0 PIPEs
  • 2026-03-04424B3offering
  • 2026-03-04EFFECTshelf_effective
  • 2026-02-24S-3shelf_registration
  • 2025-07-318-Kmaterial_agreement
  • 2024-11-14SC 13G/Astrategic_stake
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

hold · target $6 (+10% upside) · 8 analysts
  • 2026-05-06Wells FargoEqual-Weight
  • 2026-05-06TD CowenHold
  • 2026-02-24UBSNeutral
  • 2026-02-24Wells FargoEqual-Weight
  • 2025-11-11Piper SandlerOverweight
  • 2025-11-05Wells FargoEqual-Weight

Competitors

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.